title: Advances in designs for Alzheimer's disease clinical trials.
abstract: There is an urgent need to identify new treatments for the rapidly growing population of people with Alzheimer's disease (AD). Innovations in clinical trial designs many help to reduce development time, provide more definitive answers regarding drug efficacy, and facilitate prioritizing compounds to be advanced to Phase III clinical trials. Standard designs compare drug and placebo changes from baseline on a rating scale. Baysian adaptive clinical trials allow the use of data collected in the trial to modify doses, sample size, trial duration, and entry criteria in an ongoing way as the data are collected. Disease-modification is supported by findings on staggered start and delayed withdrawal designs. Futility designs can use historical controls and may shorten trial duration. Combination therapy designs may allow investigation of additive or synergistic treatment effects. Novel trial selection criteria allow investigation of treatment effects in asymptomatic or minimally symptomatic, prodromal AD populations. The Clinical Dementia Rating-Sum of Boxes (CDR-SOB) can be considered as a single trial outcome in early disease populations. Alternate forms of the Alzheimer's Disease Assessment Scale-Cognitive Portion (ADAS-cog), computerized measures, and pharmacoeconomic scales provide new and relevant information on drug effects. Comparative dose strategies are used in trials of symptomatic agents, and novel methods including withdrawal designs, symptom emergence analyses, and sequential designs are being utilized to assess the efficacy of putative psychotropic agents. The choice of trial design is driven by the question to be answered by the clinical trial; an increasing number of design approaches are available and may be useful in accelerating and refining AD drug development.
authors: Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada; Cleveland, Ohio; Weston, Florida.
authors: Jeffrey
authors: J
authors: Cummings
authors: Heath
authors: H
authors: Gould
authors: Kate
authors: K
authors: Zhong
keywords: Alzheimer’s disease; Clinical trials; designs; drug development
references: Biomark Med. 2010 Feb;4(1):3-14
references: 20383319
references: Neurology. 2009 Dec 15;73(24):2061-70
references: 19923550
references: Am J Psychiatry. 1984 Nov;141(11):1356-64
references: 6496779
references: Int Psychogeriatr. 1997;9 Suppl 1:163-5
references: 9447439
references: JAMA. 2011 Dec 21;306(23):2608-9
references: 22187281
references: Ann Neurol. 2009 Aug;66(2):235-44
references: 19743457
references: Neurology. 2005 May 10;64(9):1553-62
references: 15883316
references: J Neuropsychiatry Clin Neurosci. 2005 Winter;17(1):98-105
references: 15746489
references: Arch Neurol. 2007 Sep;64(9):1323-9
references: 17846273
references: N Engl J Med. 2005 Jun 9;352(23):2379-88
references: 15829527
references: J Psychiatr Res. 1975 Nov;12(3):189-98
references: 1202204
references: N Engl J Med. 1997 Apr 24;336(17):1216-22
references: 9110909
references: Am J Alzheimers Dis Other Demen. 2005 Nov-Dec;20(6):359-66
references: 16396441
references: Arch Neurol. 2010 Jun;67(6):746-9
references: 20558394
references: N Engl J Med. 2003 Apr 3;348(14):1333-41
references: 12672860
references: Clin Pharmacol Ther. 2009 Jul;86(1):97-100
references: 19440188
references: J Int Neuropsychol Soc. 1997 Mar;3(2):139-46
references: 9126855
references: Arch Neurol. 2012 Feb;69(2):198-207
references: 21987394
references: J Biopharm Stat. 2009;19(2):360-85
references: 19212886
references: Neurology. 2006 Mar 14;66(5):660-3
references: 16534103
references: Psychother Psychosom. 2003 May-Jun;72(3):115-27
references: 12707478
references: Psychol Med. 2002 Apr;32(3):483-91
references: 11989993
references: Lancet Neurol. 2008 Sep;7(9):779-86
references: 18672400
references: Int Psychogeriatr. 2012 May;24(5):689-97
references: 21910950
references: Ann Neurol. 2009 Jul;66(1):48-54
references: 19360898
references: Arch Clin Neuropsychol. 2005 May;20(3):403-8
references: 15797175
references: Lancet Neurol. 2012 Mar;11(3):241-9
references: 22305802
references: Alzheimers Dement. 2011 May;7(3):270-9
references: 21514249
references: Lancet Neurol. 2007 Aug;6(8):734-46
references: 17616482
references: Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S33-9
references: 9236950
references: Int Psychogeriatr. 2011 Nov;23(9):1376-85
references: 21477408
references: J Clin Pharmacol. 2012 May;52(5):629-44
references: 21659625
references: Clin Trials. 2007;4(4):309-17
references: 17848492
references: JAMA. 2004 Jan 21;291(3):317-24
references: 14734594
references: Dement Geriatr Cogn Disord. 2012;33(5):341-53
references: 22796905
references: Postgrad Med. 2009 Mar;121(2):177-85
references: 19332976
references: Alzheimers Res Ther. 2011 Jan 06;3(1):1
references: 21211070
references: Neurology. 2002 Oct 8;59(7):1042-6
references: 12370459
references: Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:50-3
references: 9305517
references: Eur Neuropsychopharmacol. 2011 Feb;21(2):159-66
references: 20933373
references: Arch Gen Psychiatry. 2011 Aug;68(8):853-61
references: 21810649
references: J Clin Epidemiol. 2005 Mar;58(3):217-25
references: 15718109
references: Alzheimers Dement. 2009 Sep;5(5):406-18
references: 19751920
references: J Biopharm Stat. 2011 Jul;21(4):846-59
references: 21516573
references: J Alzheimers Dis. 2012;31(3):507-16
references: 22614878
references: J Biopharm Stat. 2012;22(2):276-93
references: 22251174
references: Neurobiol Aging. 2013 Jan;34(1):62-72
references: 22503160
references: Alzheimers Dement. 2013 Feb;9(1 Suppl):S45-55
references: 22658286
references: Alzheimers Dement. 2010 May;6(3):257-64
references: 20451874
references: Lancet Neurol. 2010 Nov;9(11):1118-27
references: 20934914
references: Brain Imaging Behav. 2012 Dec;6(4):489-501
references: 22614326
references: BMC Neurol. 2011 May 25;11:57
references: 21612646
references: N Engl J Med. 2012 Aug 30;367(9):795-804
references: 22784036
references: Alzheimer Dis Assoc Disord. 1996 Fall;10 Suppl 1:31-5
references: 8876787
references: Alzheimers Dement. 2012 Jul;8(4):288-94
references: 22465173
references: Int Psychogeriatr. 2012 Oct;24(10):1553-60
references: 22717299
references: Arch Neurol. 2012 Jul;69(7):901-5
references: 22431834
references: Control Clin Trials. 2002 Dec;23(6):635-49
references: 12505242
references: Alzheimers Res Ther. 2011 Mar 21;3(2):9
references: 21418632
references: Neurology. 2006 Nov 28;67(10):1827-32
references: 17130417
references: Amyotroph Lateral Scler. 2008 Aug;9(4):212-22
references: 18608093
references: J Clin Exp Neuropsychol. 2006 Oct;28(7):1095-112
references: 16840238
references: Alzheimers Dement. 2011 Nov;7(6):602-610.e2
references: 21745761
references: Int J Geriatr Psychiatry. 2011 Sep;26(9):937-43
references: 21845596
references: Arch Neurol. 2012 Aug;69(8):1002-10
references: 22473769
references: Clin Trials. 2010 Apr;7(2):121-35
references: 20338905
references: Arch Clin Neuropsychol. 2006 Oct;21(7):623-43
references: 17014981
references: Lancet Neurol. 2010 Apr;9(4):363-72
references: 20189881
references: N Engl J Med. 2009 Sep 24;361(13):1268-78
references: 19776408
references: J Gerontol A Biol Sci Med Sci. 2012 Jun;67(7):766-72
references: 22573913
references: Biomark Med. 2010 Feb;4(1):81-9
references: 20387304
references: Alzheimers Dement. 2011 May;7(3):263-9
references: 21514250
references: Alzheimers Dement. 2009 Sep;5(5):388-97
references: 19751918
references: Arch Neurol. 2001 Jun;58(6):977-82
references: 11405813
references: Alzheimers Dement. 2011 Jul;7(4):367-85
references: 21784348
references: J Nutr Health Aging. 2010 Oct;14(8):640-7
references: 20922340
references: Alzheimers Dement. 2011 May;7(3):280-92
references: 21514248
references: Clin Trials. 2011 Feb;8(1):5-14
references: 21335586
references: Neurology. 2006 Mar 14;66(5):628-33
references: 16534099